Dividend Yield
Dividend yield is calculated by dividing the annual dividend per share by the price per share or the annual dividend by the market cap. A high dividend yield could reflect stocks that are undervalued and will provide a higher return. To determine if a dividend yield is high, it is often compared to the market yield. For example, the average dividend yield for the S&P 500 over the the last six decades leading up to 2013 is 3.4%. Using this as a benchmark, any yield above this mark is attractive. Rising dividend yield can be the result of two occurrences: a falling stock price or a rising dividend payout, the latter being preferable. Another use of dividend yield is to compare it to the yield on 10-year treasuries. If an investment's dividend yield is greater than the treasury yield, then that investment is attractive given that the risk profile is not too high.
Top 5 Long Term Companies To Buy For 2015: Axxess Pharma Inc (AXXE)
Axxess Pharma Inc. is a pharmaceutical company. It is engaged in marketing of dermatological, therapeutic nutritionals, pain management, and diagnostic products in Canada and abroad. In October 2013, the Company announced that it has incorporated a wholly owned subsidiary AllStar HealthBrands Inc.
The Company various products include Britical Tablets, Gravergol Capsules, Lactrase Capsules, Somnol Tablets, Triferexx -150 Polysaccharide-iron complex, Urasal Granules, Axspaz Tablets, Vivol Tablets, Hydraxx Lotion, Kemsol Solution, Soropon shampoo, and Skin care Products. Its distribution network includes physicians, hospitals, Government and defense institutions, and pharmacies.
Advisors' Opinion:- [By Peter Graham]
Small cap health care or personal care stocks Axxess Pharma Inc (OTCMKTS: AXXE), Radiant Creations Group Inc (OTCBB: RCGP) and Tauriga Sciences Inc (OTCMKTS: TAUG) have recently been attracting attention in various investment newsletters or in investor alerts. Some of the attention may have to do with paid promotions that two of these small caps have been the subject of. So how healthy are these three small cap health care or personal care orientated stocks? Here is a checkup:
- [By Peter Graham]
Small cap healthcare and lifestyle stocks Axxess Pharma Inc (OTCMKTS: AXXE), Medefile International Inc (OTCMKTS: MDFI) and Intelligent Living Inc (OTCMKTS: ILIV) have all been getting some extra attention lately thanks in part to a few disclosed paid promotions or investor relations type of activities. But just how healthy are these small cap stocks for investors and traders alike? Here is a quick reality check:
Axxess Pharma Inc (OTCMKTS: AXXE) Has Been Busy With the Press ReleasesSmall cap Axxess Pharma is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. On Friday, Axxess Pharma fell 7.52% to $0.295 for a market cap of $12.46 million plus AXXE is down 88.8% over the past year and down 99.8% over the past five years in intermittent trading according to Google Finance.
Top High Dividend Stocks To Own For 2014: Kinder Morgan Management LLC (KMR)
Kinder Morgan Management, LLC is a limited partner in Kinder Morgan Energy Partners, L.P (KMP), and manages and controls its business and affairs pursuant to a delegation of control agreement. Kinder Morgan G.P., Inc., of which Kinder Morgan, Inc. indirectly owns all of the outstanding common equity, is the general partner of Kinder Morgan Energy Partners, L.P. (KMP). Kinder Morgan G.P., Inc., pursuant to a delegation of control agreement among the Company, Kinder Morgan G.P., Inc. and KMP, has delegated to the Company, to the fullest extent permitted under Delaware law and KMP�� limited partnership agreement, all of its rights and powers to manage and control the business and affairs of KMP, subject to the general partner�� right to approve specified actions.
KPM is a pipeline limited partnerships in the United States. KMP owns an investment in or operates approximately 28,000 miles of pipelines and 180 terminals. Its pipelines transport products, such as natural gas, crude oil, gasoline, and CO2, and its terminals store petroleum products and chemicals and handle materials like coal. Almost all of Kinder Morgan assets are owned by KMP, KMP operates in five business segments : Natural Gas Pipelines, Products Pipelines, CO2, Terminals and Kinder Morgan Canada.
Kinder Morgan is a transporter and marketer of carbon dioxide in North America. It delivers approximately 1.3 billion cubic feet per day of CO2 through about 1,300 miles of pipelines. It is an oil producer in Texas, producing over 55,000 barrels of oil per day at the SACROC Unit and the Yates Field in the Permian Basin. In addition to CO2 pipelines and oil producing fields, this business segment owns interests in and operates CO2 source fields, natural gas and gasoline processing plants, and a crude oil pipeline. Kinder Morgan owns and operates approximately 24,000 miles of gas pipelines in the Rocky Mountains, the Midwest and Texas. Through its Products Pipelines business unit, it transports over two million barre! ls per day of gasoline, jet fuel, diesel, natural gas liquids and other fuels through more than 8,000 miles of pipelines. The Company also has approximately 50 liquids terminals in this business segment that store fuels and offer blending services for ethanol and other products.
Kinder Morgan have more than 180 terminals that store petroleum products and chemicals, and handle bulk materials like coal, petroleum coke and steel products. Kinder Morgan operates a number of pipeline systems and terminal facilities in Canada including the Trans Mountain pipeline, the Express and Platte pipelines, the Cochin pipeline, the Puget Sound and the Trans Mountain Jet Fuel pipelines, the Westridge marine terminal, the Vancouver Wharves terminal in British Columbia and the North Forty terminal in Edmonton, Alberta.
Advisors' Opinion:- [By The Part-time Investor]
I sold Kinder Morgan Energy Partners (KMP), 168 shares at $80.38, and I replaced it with Kinder Morgan Management (KMR), 264 shares at $75.39. KMR pays its quarterly distribution in extra shares, rather than in cash, as KMP does. For some (crazy) reason this makes it okay to hold it in a retirement account without the tax implications.
- [By Adam Galas]
However, investors should largely ignore this bottom-line miss, because in actuality Kinder Morgan is firing on all cylinders and had great news about its acquisition of�Kinder Morgan Energy Partners (NYSE: KMP ) , Kinder Morgan Management (NYSE: KMR ) , and El Paso Pipeline Partners (NYSE: EPB ) .�
Top High Dividend Stocks To Own For 2014: Apollo Gold Corporation(BRD)
Brigus Gold Corp. engages in the extraction, processing, refining, and production of gold and other by-product metals primarily in North America. The company principally produces gold and silver. It primarily owns the Black Fox Complex and Black Fox Mill properties located in the Timmins Mining District in the Province of Ontario, Canada; the Goldfields project located in the Lake Athabasca region of Saskatchewan, Canada; and the Ixhuatan property located in the state of Chiapas, Mexico. Brigus Gold Corp., through its joint venture, holds interests in the Ampliacion Pueblo Viejo and Loma El Mate gold exploration projects located in the Dominican Republic. The company was formerly known as Apollo Gold Corporation and changed its name to Brigus Gold Corp. in June 2010. Brigus Gold Corp. was founded in 1936 and is headquartered in Halifax, Canada.
Advisors' Opinion:- [By Zacks Investment Research]
It is hard to find a good play in the Zacks Industry of mining non-ferrous metals, as the industry currently has a rank of 247 out of 261. In fact, in our five mining industries, there are only two No. 1-Ranked stocks: Brigus Gold (BRD) and Impala (IMPUY.PK). Both of these are in struggling industries, but they have proven to be best-in-class thanks to improving earnings estimates. Plus, both have seen their ranks surge from holds (or worse) up to strong buy territory, suggesting either of these names might be better picks than the struggling SCCO at this time.
- [By MONEYMORNING]
As well, Primero Mining (NYSE: PPP) bought Brigus Gold Corp (USA)(NYSE: BRD) for $220 million, and Asanko Gold (NYSEMKT: AKG) is acquiring PMI Gold Corporation (TSE: PMV).
Top High Dividend Stocks To Own For 2014: Tencent Holdings Ltd (TCEHY)
Tencent Holdings Limited is an investment holding company. The Company and its subsidiaries are principally engaged in the provision of Internet value-added services, mobile and telecommunications value-added services and online advertising services to users in the People�� Republic of China. The Company operates in four segments: Internet value-added services, Mobile and telecommunications value-added services, Online advertising, and Others. As of December 31, 2011, its subsidiaries included Tencent Cyber (Tianjin) Company Limited, Tencent Asset Management Limited, Tencent Technology (Beijing) Company Limited, Tencent Cyber (Shenzhen) Company Limited, Tencent Technology (Shanghai) Company Limited and others. Advisors' Opinion:- [By Damian Illia]
The company has a current ratio of 11.8% which is higher than the one registered by Facebook (FB), InterXion Holding N.V. (INXN) and AOL Inc. (AOL). But for investors looking for a higher ROE, Tencent Holdings Ltd. (TCEHY) could be the option.
Top High Dividend Stocks To Own For 2014: Fifth Street Senior Floating Rate Corp (FSFR)
Fifth Street Senior Floating Rate Corp., incorporated on May 22, 2013, is a closed-end, non-diversified management investment company. The Company investment objective is to maximize the Company�� portfolio�� total return by generating income from its debt investments while seeking to preserve its capital. The Company intends to achieve its investment objective by investing primarily in senior secured loans, including first lien, unitranche and second lien debt instruments, that pay interest at rates, which are determined periodically on the basis of a floating base lending rate, made to private middle market companies whose debt is rated below investment grade, which the Company refer to collectively as senior loans. The Company�� investment adviser is Fifth Street Management.
The Company may also invest in senior unsecured loans issued by private middle market companies and, to a lesser extent, subordinated loans issued by private middle market companies and senior and subordinated loans issued by public companies. Under normal market conditions, at least 80% of the value of its net assets plus borrowings for investment purposes will be invested in floating rate senior loans. Senior loans pay interest at rates, which are determined periodically on the basis of the London-Interbank Offered Rate (LIBOR) plus a premium. Senior loans in which the Company expects to invest are made to United States and, to a limited extent, non- United States corporations, partnerships and other business entities which operate in various industries and geographical regions.
Advisors' Opinion:- [By Marc Bastow]
Management investment company Fifth Street Senior Floating Rate Corp. (FSFR) raised its quarterly dividend 15% to 23 cents per share, payable April 15 to shareholders of record as of March 31.
FSFR Stock�Dividend Yield: 6.88%
Top High Dividend Stocks To Own For 2014: Hemispherx Biopharma Inc (HEB)
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.
Ampligen
Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.
Alferon N Injection
Alferon N Injection is the registered trademark for the Company's injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company's natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.
Alferon LDO (Low Dose Oral)
Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.
The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.
Advisors' Opinion:- [By MONEYMORNING]
Hemispherix Biopharma Inc. (NYSE: HEB) is a specialty pharmaceutical company. It engages in the clinical development of new drug therapies based on natural immune system enhancing technologies and targets the treatment of viral and immune-based clinical disorders. The Philadelphia, Pa.-headquartered company gained widespread attention over the last several months for its work on flu research. Its flagship products include Alferon N Injection, approved by the FDA for a category of sexually transmitted disease infection. Experimental treatments include Ampligen and Oragens, in development stages for the potential treatment of global viral diseases and disorders of the immune system including human papilloma virus, human immunodeficiency virus, chronic fatigue syndrome, hepatitis, and influenza. Shares have traded as low as $0.18 and as high as $0.55 over the last year. At last check, shares were changing hands around $0.50 on volume of 2 million shares.
- [By Matt Egan]
Shares of Hemispherx Biopharma (HEB) soared 11% on Wednesday amid the rising Ebola fears. Earlier this week, the company announced a series of research collaborations aimed at developing treatments to fight Ebola.
No comments:
Post a Comment